BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung
BNT323-01
Phase 3 small_molecule active
Quick answer
BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung for Endometrial cancer is a Phase 3 program (small_molecule) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioNTech Manufacturing GmbH
- Indication
- Endometrial cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active